All In Biotech

Drug Trial Radar · NCT06649812

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

A Phase II Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed or Refractory CD10-Negative Diffuse Large B-Cell Lymphoma (DLBCL) and High-Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements (HGBCL-DH-BCL2)

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Oct 7, 2025

Primary completion

Sep 1, 2028

Study completion Sep 1, 2028

Sponsor

Sponsor type
NIH
First posted
Oct 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearrangements that has come back after a period of improvement (relapsed) and/or that has not responded to previous treatment (refractory). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Ibrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers at abnormal levels. This may help keep cancer cells from growing and spreading. Anti-inflammatory drugs, such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Obinutuzumab, a monoclonal antibody, binds to a protein called CD20, which is found on B cells and some types of leukemia and lymphoma cells. Obinutuzumab may block CD20 and help the immune system kill cancer cells. Revlimid, a type of anti-angiogenesis agent and a type of immunomodulating agent, may help the immune system kill abnormal blood cells or cancer cells. It may also prevent the growth of new blood vessels that cancers need to grow. ViPOR may be an effective treatment option for patients with relapsed and/or refractory CD10 negative DLBCL and high-grade B-cell lymphoma with MYC and BCL2 rearrangements.

Conditions

  • High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
  • Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
  • Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
  • Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
  • Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
  • Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
  • Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
  • Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified
  • Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma

Interventions

  • Biopsy ProcedureProcedure

    Undergo optional tumor biopsy

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Bone Marrow AspirationProcedure

    Undergo bone marrow aspiration and biopsy

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow aspiration and biopsy

  • Computed TomographyProcedure

    Undergo CT

  • IbrutinibDrug

    Given PO

  • LenalidomideDrug

    Given PO

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • ObinutuzumabBiological

    Given IV

  • Positron Emission TomographyProcedure

    Undergo PET

  • PrednisoneDrug

    Given PO

  • VenetoclaxDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete response (CR) rate (CD10-negative diffuse large B cell lymphoma [DLBCL] and high grade B-cell lymphoma with MYC and BCL2 with or without BCL6 rearrangements [HGBCL-DH-BCL2])Time frame: Up to 5 years

Locations

115 sites in 1 country. Site status is shown where the registry gives one.

  • Banner University Medical Center - Tucson

    Tucson, Arizona · Active not recruiting

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona · Active not recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • Smilow Cancer Hospital-Derby Care Center

    Derby, Connecticut · Recruiting

  • Smilow Cancer Hospital Care Center - Guilford

    Guilford, Connecticut · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • Kootenai Health - Coeur d'Alene

    Coeur d'Alene, Idaho · Recruiting

  • Kootenai Clinic Cancer Services - Post Falls

    Post Falls, Idaho · Recruiting

  • Kootenai Clinic Cancer Services - Sandpoint

    Sandpoint, Idaho · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • Carle at The Riverfront

    Danville, Illinois · Suspended

  • Northwestern Medicine Cancer Center Kishwaukee

    DeKalb, Illinois · Recruiting

  • Carle Physician Group-Effingham

    Effingham, Illinois · Suspended

  • Northwestern Medicine Cancer Center Delnor

    Geneva, Illinois · Recruiting

  • Northwestern Medicine Glenview Outpatient Center

    Glenview, Illinois · Recruiting

  • Northwestern Medicine Grayslake Outpatient Center

    Grayslake, Illinois · Recruiting

  • Northwestern Medicine Lake Forest Hospital

    Lake Forest, Illinois · Recruiting

  • Carle Physician Group-Mattoon/Charleston

    Mattoon, Illinois · Suspended

  • Carle BroMenn Medical Center

    Normal, Illinois · Suspended

  • Carle Cancer Institute Normal

    Normal, Illinois · Suspended

  • Northwestern Medicine Oak Brook

    Oak Brook, Illinois · Recruiting

  • Northwestern Medicine Orland Park

    Orland Park, Illinois · Recruiting

  • Memorial Hospital East

    Shiloh, Illinois · Recruiting

  • Carle Cancer Center

    Urbana, Illinois · Suspended

  • Northwestern Medicine Cancer Center Warrenville

    Warrenville, Illinois · Recruiting

  • Northwest Cancer Center - Crown Point

    Crown Point, Indiana · Recruiting

  • Northwest Oncology LLC

    Dyer, Indiana · Recruiting

  • Saint Mary Medical Center

    Hobart, Indiana · Recruiting

  • Saint Catherine Hospital

    Indianapolis, Indiana · Recruiting

  • The Community Hospital

    Munster, Indiana · Recruiting

  • Women's Diagnostic Center - Munster

    Munster, Indiana · Recruiting

  • Northwest Cancer Center - Valparaiso

    Valparaiso, Indiana · Recruiting

  • Mary Greeley Medical Center

    Ames, Iowa · Recruiting

  • McFarland Clinic - Ames

    Ames, Iowa · Recruiting

  • UI Health Care Mission Cancer and Blood - Ankeny Clinic

    Ankeny, Iowa · Recruiting

  • McFarland Clinic - Boone

    Boone, Iowa · Suspended

  • Saint Anthony Regional Hospital

    Carroll, Iowa · Recruiting

  • Mercy Hospital

    Cedar Rapids, Iowa · Recruiting

  • Oncology Associates at Mercy Medical Center

    Cedar Rapids, Iowa · Recruiting

  • UI Health Care Mission Cancer and Blood - West Des Moines Clinic

    Clive, Iowa · Recruiting

Showing 40 of 115 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.